Physician profile
Ellen Ablog Dy
NPI 1053317578
$3,540.76
in general payments reported to CMS, 2019-2025
25 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.80 · 2020: $87.95 · 2021: $39.09 · 2022: $558 · 2023: $433 · 2024: $1,135 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744 · Education: $18.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.27 |
| Education | $18.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.97 | 2019-2025 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $463.11 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $248.09 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $244.79 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $195.75 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $186.30 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $178.09 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $141.24 | 2020-2025 | |
| Celgene Corporation | $109.25 | 2022-2024 | Zeposia |
| Pfizer INC. | $93.96 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $91.16 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.16 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $67.65 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $63.47 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $59.26 | 2023-2024 | Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $48.85 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $40.56 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $34.48 | 2024-2025 | Zenpep |
| Organon LLC | $30.15 | 2024 | |
| Axonics, INC. | $28.72 | 2023 | Bulkamid, Axonics |
| Allergan, INC. | $23.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.22 | 2023 | Cyltezo |
| Boston Scientific Corporation | $14.98 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.33 | 2022 | |
| Qol Medical, LLC | $12.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Dy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.